New pill for chronic hives and skin disease tested – but study halted early

NCT ID NCT06555328

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral drug called INF904 in people with moderate to severe chronic spontaneous urticaria (long-term hives) or hidradenitis suppurativa (a painful skin condition). The trial was open-label and lasted 28 days of treatment plus follow-up. It aimed to check safety and how the drug moves through the body. However, the study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
INF904 (an oral C5aR1 inhibitor)
What this could lead to
If successful, INF904 could offer a new oral treatment option for people with chronic hives or hidradenitis suppurativa.
What could go wrong
This was an early (Phase 2a) study that was terminated, so results are limited. The drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC URTICARIA, IDIOPATHIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • "Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spolka Partnerska"

    Wroclaw, 50-566, Poland

  • "Institut Allergieforschung Charité - Universitatsmedizin Berlin"

    Berlin, 12203, Germany

  • "Klinikum der Universitat (LMU) Klinik und Poliklinik far Dermatologie und Allergologie"

    München, 80337, Germany

  • ASMC IPSMC Skin and Venereal Diseases,

    Sofia, 1407, Bulgaria

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • First OC Dermatology Research Inc.

    Fountain Valley, California, 92708, United States

  • ForCare Clinical Research

    Tampa, Florida, 33613, United States

  • Forest Hills Dermatology Group

    Kew Gardens, New York, 11415, United States

  • General Hospital of Thessaloniki "Papageorgiou"

    Thessaloniki, 56403, Greece

  • General University Hospital "Attikon"

    Athens, 12462, Greece

  • Katholisches Klinikum Bochum gGmbH/ St.Josef-Hospital Bochum, Dermatologie

    Bochum, 44791, Germany

  • Kentucky Advanced Medical Research LLC

    Murray, Kentucky, 42071, United States

  • Klinika Dermatologii, Wenerologii i Alergologii, UNIWERSYTECKIE CENTRUM KLINICZNE, ul.

    Gdansk, 80-214, Poland

  • LLC "Aversi Clinic"

    Tbilisi, 0160, Georgia

  • LLC "Center of Allergy and Immunology"

    Tbilisi, 0159, Georgia

  • LTD "Health"

    Batumi, 6010, Georgia

  • LTD "Israel-Georgian Medical Research Clinic Healthycore"

    Tbilisi, 0112, Georgia

  • Labderm Essence sp.

    Ossy, 42-624, Poland

  • MediSearch LLC

    Saint Joseph, Missouri, 64506, United States

  • Medical Center Etika

    Plovdiv, 4200, Bulgaria

  • Medical Center Excelsior OOD,

    Sofia, 1407, Bulgaria

  • Medical Center Medconsult pleven OOD

    Pleven, 5800, Bulgaria

  • Medical Center Medconsult, Pleven OOD

    Lovech, 5500, Bulgaria

  • Oddziat Kliniczny Wewnetrznych, Astmy i Alergii z Odcinkiem dla Dzieci, Samodzielny Publiczny Zaktad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny

    Lodz, 90-153, Poland

  • Progressive Clinical Research, PA

    Texas City, Texas, 78213, United States

  • Universitatsklinikum Dresden Carl Gustav Carus

    Dresden, 01307, Germany

  • Universitätsklinikum Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie

    Frankfurt, 60950, Germany

  • Wright State Physicians

    Fairborn, Ohio, 45324, United States

  • Ziaderm Research LLC

    North Miami Beach, Florida, 33162, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.